Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). University of Arizona Cancer Center initiated investigator-sponsored PEDMARK study in adolescent, young adult, and adult cancer patients.
FENNEC PHARMACEUTICALS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- University of Arizona Cancer Center initiated investigator-sponsored PEDMARK study in adolescent, young adult, and adult cancer patients
- Study evaluates PEDMARK alongside cisplatin for head and neck and testicular cancers
- Potential label-expansion opportunity beyond current pediatric use, but clinical and regulatory outcomes remain uncertain
- Press release furnished as Exhibit 99.1 for study details
Item EX-99.1 · Exhibit EX-99.1
- University of Arizona initiating Phase I/II study of PEDMARK in AYA and adult head-and-neck and testicular cancer patients receiving cisplatin
- Study evaluates hearing-loss reduction versus historical controls and cisplatin elimination up to 6 hours after infusion
- Expands real-world evidence beyond PEDMARK’s FDA-approved pediatric population and supports potential label expansion
- Three institution-led studies initiated within recent months, strengthening validation across adult and AYA populations
- Cisplatin-associated hearing loss affects 60%-90% of treated patients, highlighting substantial unmet need and commercial opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FENNEC PHARMACEUTICALS INC. 8-K filings
Get the next FENC 8-K as it lands
Follow FENC for push alerts, or ask the research agent what this filing means.